The Stand Up to Cancer Phillip A. Sharp Innovation in Collaboration Awards: Enabling Cooperation to Benefit Patients
Collaboration among scientists and different institutions is one of the hallmarks of Stand Up To Cancer. To encourage this, SU2C awards grants every year to scientists on different teams within the SU2C research community who propose new and potentially fruitful ways of working with each other. These Phillip A. Sharp Innovation in Collaboration Awards are named for the Nobel Laureate and chairman of the SU2C Scientific Advisory Committee, who has always insisted on a high level of collaboration within SU2C's work.
Dr. Sharp (center) with awardees in 2019.
Here is a list of selected awards made through 2019. Click on the year for details.
Resistance to PARP inhibitor plus anti-PD1 therapy driven by ER stress and bioactive lipids in ovarian cancer. Alan D'Andrea, MD, and Juan Cubillos-Ruiz, PhD
Uncovering mutant TP53 dependencies in spontaneously arising triple-negative breast cancer. Denada Dibra, PhD, and Peter P. Lee, MD
Non-invasive monitoring of tumor phenotype by interrogation of plasma cell-free RNA. Maximilian Diehn, MD, PhD, and Aaron Hata, MD, PhD
Precision combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR) signaling in pediatric and young adult CRLF2-rearranged ALL. Sarah Tasian, MD, and Kimberly Stegmaier, MD
Antigenicity of mutant KRAS and impact on cancer evolution. Robert H. Vonderheide, MD, DPhil, and Vinod P. Balachandran, MD
Cupid-seq: high throughput transcriptomic spatial mapping of micro-environment immune-tumor interactions: Dan Landau, MD, PhD, and Raul Rabadan, PhD
Characterizing immune-variability in children following standard-of-care treatment to enable precision assignment to immunotherapy trials: Trevor J. Pugh, PhD, and David M. Barrett, MD
Interrogating impact of epigenetic modifiers on durable reprogramming of exhausted CD8 T cells in patients with NSCLC: E. John Wherry, PhD, and Matthew Hellman, MD
Studies of colorectal cancer patient-derived organoids to validate candidate biomarkers of resistance to natural killer cells: Michal Sheffer, PhD, and Hugo J. Snippert, MD
Aptamer-based detection and binding of peptide-MHC: Cassian Yee, MD, and Bruce Sullenger, PhD
Interrogation of resistance mechanisms to checkpoint inhibitors using functional genomics: Siwen Hu-Lieskovan, MD, PhD, and Rene Bernards, PhD
Dissecting the epigenetic mechanisms of repeat RNA regulation in cancer: David T. Ting, MD, and Shelley Berger, PhD
Probing the metabolic interactions between tumor and stroma in pancreatic cancer: Matthew G. Vander Heiden, PhD, and Melissa C. Skala, PhD
Defining the role of epigenetics in chimeric antigen receptor T cell therapy for CLL: Shelley Berger, PhD, and Carl June, MD
Towards predictive models of immunotherapy response: Benjamin D. Greenbaum, PhD, and Jedd D. Wolchok, MD, PhD
Genetic heterogeneity of pancreatic cancer: Hans Clevers, MD, PhD, and David A. Tuveson, MD, PhD
Targeting epigenetic plasticity and drug resistance in pediatric cancer: Kimberly Stegmaier, MD, and Adolfo A. Ferrando, MD, PhD
The intersection of epigenetic and immune checkpoint therapy: Stephen B. Baylin, MD, and James P. Allison, PhD
cBioPortal for Stand Up To Cancer: David B. Solit, MD, and Nikolaus Schultz, PhD
Analysis of high-dimension single-cell data from cancer immunotherapy clinical trials: Dana Pe’er, PhD, and Padmanee Sharma, MD, PhD